Background Investigators and research teams participating in clinical trials have to deal with complex investigational products, study designs, and research environments. The emergence of new drug delivery systems and investigational products combining more than one drug and the development of biodrugs such as monoclonal antibodies, peptides, siRNA, and gene therapy to treat orphan or common diseases constitute a new challenge for investigators and clinical sites.
Purpose We describe the requirements and challenges of drug management in conformity with Good Clinical Practices (GCPs) for investigators and sites participating in clinical trials.
Review At all sites participating in clinical trials, standard operating procedures (SOPs) covering the critical path of drug and drug delivery systems management are required. All steps should be auditable, including reception, validation, storage, access, preparation, distribution, techniques of administration, use, return, and destruction of research products. Biodrugs require traceability and specific SOPs on the management of potential immune reactions. Investigational products must be stored under standard auditable conditions. The traceability of storage conditions (including temperature) requires these conditions to be monitored on a continuous basis. A dedicated space with restricted access limited to authorized qualified personnel facilitates the monitoring.
Conclusions The development of standardized, auditable settings and the application of dedicated, site-specific SOPs for the management of investigational products and drug delivery systems contribute to guarantee the compliance to GCP requirements.
Get full access to this article
View all access options for this article.
References
1.
International Conference on Harmonisation (ICH). International conference on harmonisation, requirements for registration of pharmaceuticals, harmonised tripartite guideline (including E6: Guideline for Good Clinical Practice (GCP). 1996. Available at http://www.ich.org (accessed December 2011).
European Medicines Agency (EMA). ICH Topic E 6. Guideline for Good Clinical Practice, 2002. Available at http://www.ema.europa.eu/ (accessed December 2010).
Fonds de la recherche en santé du Québec (FRSQ). Standard Operating Procedures (SOP) to Ensure Good Clinical Practice at Clinical Research Sites, 2007. Available at http://www.frsq.gouv.qc.ca/en/financement/SOP.shtml (accessed December 2010).
7.
Royal Pharmaceutical Society of Great Britain. Practice Guidance on Pharmacy Services for Clinical Trials. Royal Pharmaceutical Society of Great Britain, London, 2005.
8.
MéthotJLefebvreCArsenaultSGaudetD. Biobanking solution adapted to the needs of sites participating in clinical trials conducted in collaboration with the pharmaceutical industry. In: ISBER 2010 Annual Meeting, Rotterdam, the Netherlands, Biopreservation Biobanking2010; 7: 190–91.
9.
SatherMRRaischDWHaakensonCMBuckelewJMFeussnerJR. Promoting good clinical practices in the conduct of clinical trials: Experiences in the Department of Veterans Affairs Cooperative Studies Program. Control Clin Trials2003; 24: 570–84.
10.
WermelingDP. Clinical research: Regulatory issues. Am J Health Syst Pharm1999; 56: 252–56.
Food and Drug Administration (FDA). Counterfeit Drug Task Force Report 2006 Section V: What Technical Issues Related to Electronic Track and Trace Need Resolution?2006. Available at http://www.fda.gov/Drugs/DrugSafety/ucm172899.htm (accessed May 2011).
13.
KeinonenTKeranenTKlaukkaT. Pharmaceutical industry’s barriers and preferences to conduct clinical drug trials in Finland: A qualitative study. Eur J Pharm Sci2003; 20: 35–42.
14.
CrammondBRParkerAVBrooksMSkibaMMcNeilJJ. Self-audit as part of a research governance framework for health research. Med J Aust2011; 194: 310–12.
15.
GoldhammerA. Current issues in clinical research and the development of new pharmaceuticals. Account Res2001; 8(4): 283–91.
16.
KuusistoHVirkkiMWuolijokiEKeranenT. Hospital training program increases awareness of good clinical practice (GCP). Contemp Clin Trials2011; 32: 339–41.
PhillipsMS. Clinical research: ASHP guidelines and future directions for pharmacists. Am J Hosp Pharm1999; 15: 344–46.
19.
Société canadienne des pharmaciens d’hôpitaux. Lignes directrices sur l’utilisation des médicaments pour des essais cliniques en établissements de santé. Publications officielles2003/2004: 55–58.
20.
RogersKCFinksSW. Job sharing for women pharmacists in academia. Am J Pharm Educ2009; 73: 135.
21.
PedersenCASchneiderPJScheckelhoffDJ. ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education–2003. Am J Health Syst Pharm2004; 61: 457–71.
22.
BablFESharwoodLN. Research governance: Current knowledge among clinical researchers. Med J Aust2008; 188: 649–52.
23.
van DongenAJ. Good clinical practice, a transparent way of life. A review. Comput Med Imaging Graph2001; 25: 213–16.
24.
SweatmanJ. Good clinical practice: A nuisance, a help or a necessity for clinical pharmacology?Br J Clin Pharmacol2003; 55: 1–5.
